Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treatment of inflammatory disease

a technology for inflammatory diseases and compositions, applied in the field of methods and compositions for treating inflammatory diseases, can solve the problems of significant adverse side effects, and certain therapies which provide relief from symptoms of inflammatory diseases may not be effective in treating the underlying causes of the disease, and achieve the effect of enhancing absorption

Inactive Publication Date: 2007-01-25
LEVIN BRUCE
View PDF13 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The invention disclosed herein relates to the use of cetyl myristoleate (CMO) and CMO compounds in combination with other compounds useful for treating inflammatory disease. The invention is useful for protection against the development of arthritis and other inflammatory diseases and to provide relief of symptoms in individuals where such disease has been diagnosed. Cetyl myristoleate compounds have herein been found to be particularly useful when used in combination with components of accepted therapies. When used in this manner, cetyl myristoleate compounds can provide significant symptomatic relief.
[0008] Certain pharmaceutically active compounds or combinations thereof can be coadministered with CMO compounds, but can have significant adverse side effects. Coadministration with CMO compounds allows the use of reduced amounts of such treatment components and reduction or elimination of their undesired or detrimental side effects.
[0012] The invention discloses compositions and methods for topical treatment of inflammation resulting from envenomation or contact with other irritants. Such compositions comprise local anaesthetics, either alone, or in combination with one or more of proteases, steroids, tetracycline compounds, and CMO compounds. Such compositions may further comprise ingredients which enhance absorption.

Problems solved by technology

Certain pharmaceutically active compounds or combinations thereof can be coadministered with CMO compounds, but can have significant adverse side effects.
Certain therapies which provide relief from symptoms of inflammatory disease may not be effective for treating underlying causes of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment of Arthritis with a CMO Compound and a Tetracycline Compound

[0055] A middle-aged female who suffered from knee arthritis and did not respond well to CMO therapy. NSAID drugs gave some relief, but pain was still severe. NSAID therapy was halted and tetracycline therapy was added. Rapid and effective symptomatic control was obtained. When tetracycline or CMO treatment was discontinued, symptoms worsened despite increase in dose of the remaining agent. Maximum relief was obtained with a combination of a tetracycline compound and a CMO compound.

example 2

Treatment of Arthritis with a CMO Compound and Doxycycline

[0056] A femal senior citizen who suffered from ankle and knee arthritis pain obtained no or minimal relief with CMO therapy. Doxycycline was added with excellent results noted. Symptoms returned when CMO compound or doxycycline was discontinued.

example 3

Treatment of Arthritis with a CMO Compound and Doxycycline

[0057] Doxycycline therapy was used for treatment of a middle aged male suffering from bilateral hip arthritis and experiencing severe pain despite increasing doses of NSAIDs. Rapid relief of pain to a more acceptable level was obtained with the addition of doxycycline but gastrointestinal upset was problematic. Cox-2 inhibitors were substituted for the NSAID agents with better results. However, over time, it was necessary to increase the doses of both agents to two to three times the initial dose in order to maintain adequate symptomatic relief. Side effects noted at that time included dizziness, nausea and abdominal pain. A CMO compound was added and the dosage of the other agents decreased to initial levels. The side effects disappeared and improved symptomatic relief was noted. The Cox-2 agent was discontinued with no increase in severity of symptoms. Attempts to discontinue doxycycline were unsuccessful, with symptoms i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
enzyme activityaaaaaaaaaa
compositionsaaaaaaaaaa
Login to View More

Abstract

Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a division of U.S. patent application Ser. No. 10 / 756,695, filed Jan. 12, 2004, which is a continuation of U.S. patent application Ser. No. 09 / 724,645, Filed Nov. 28, 2000, which claims priority under 35 USC 119(e) to Provisional Application No. 60 / 169,845, filed Dec. 9, 1999, each of which is expressly incorporated by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention provides compositions and methods for prevention and treatment of arthritis and other inflammatory and autoimmune diseases. BACKGROUND OF THE INVENTION [0003] The present invention relates to a method for treating inflammatory disease to prevent or delay the progression of the disease process or to alleviate the symptoms thereof. Diseases and disorders which have significant inflammatory components are ubiquitous. Skin disorders, bowel disorders, certain degenerative neurological disorders, arthritis, autoimmune diseases and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/48A61L15/00A61K9/127A61K31/24A61K31/23A61K31/65A61K45/06
CPCA61K9/0014A61K31/23A61K31/24A61K31/56A61K31/65A61K45/06A61K2300/00
Inventor LEVIN, BRUCE
Owner LEVIN BRUCE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com